Gene therapy developer CRISPR Therapeutics AG (CRSP) is navigating some regulatory and commercial dynamics. Its flagship gene ...

Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

Vertex Pharmaceuticals (NASDAQ ... including one approved early this year. CRISPR Therapeutics (NASDAQ: CRSP) is a biotech that generally tackles specialties different from those of Vertex ...

Vertex Pharmaceuticals (NASDAQ ... what they believe are the 10 best stocks to buy right now. Learn More » CRISPR Therapeutics (NASDAQ: CRSP) is a biotech that generally tackles specialties ...

Adria Cimino has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. CRISPR ...

Learn more about whether Amarin Corporation plc or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The Food and Drug Administration has approved the world’s first medicine based on CRISPR gene-editing technology, a ...